Renovacor (Chardan Healthcare Acquisition 2) ^{Priced, NYSE American: RCOR.XX}

We are a blank check company formed in 2018. Our efforts to identify a prospective target business will not be limited to any particular industry or geographic region, although we intend to focus our search on target businesses operating in North America in the healthcare industry. Chardan supports both public and private healthcare companies at various stages of a company’s life cycle, and has advised or supported capital raises for new company formation to follow-on offerings. Since 2015, Chardan has met with more than 1,000 private healthcare companies and, we believe, has earned a reputation for conducting business with healthcare companies that develop and deploy disruptive technologies. Our management team is led by Dr. Gbola Amusa, Mr. Jonas Grossman and Mr. George Kaufman each has extensive experience in healthcare both before and during their current tenure at Chardan. Together, Mr. Grossman, Mr. Kaufman, and their teams have acted as underwriter on 75 SPAC IPO’s since 2004 that generated gross proceeds of approximately $9.1 billion. Since the beginning of 2016, Chardan has ranked as the most active book running or lead-managing underwriter of SPAC IPO’s, acting in such capacity on 28 SPAC IPO’s that raised gross proceeds of approximately $3.2 billion in that period.